SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as the market keenly anticipates a pivotal Department of Energy announcement regarding surplus plutonium awards, a key catalyst for its advanced nuclear technology. Bullish sentiment is driven by expectations of government support and institutional accumulation during a perceived oversold period. Conversely, bears emphasize substantial insider selling and ongoing share dilution, raising concerns about the company's valuation given its current lack of commercial revenue.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

EKSO is experiencing significant upward momentum and trading volume following the announcement of a proposed business combination with Applied Digital's cloud division, forming a new AI compute platform, ChronoScale. The community is actively discussing this pivot into AI infrastructure, with many anticipating a substantial short squeeze despite lingering concerns about potential dilution. This move highlights EKSO's transformation into a key player in the rapidly expanding AI sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing significant volatility and trending amid intense community debate. A recent sharp rebound from declines, attributed by many to alleged manipulation via margin calls, is fueling discussion of a potential short squeeze. The market is buzzing with anticipation over imminent silver export restrictions from China, effective January 1st, 2026, which bulls believe will profoundly impact supply and drive prices higher due to rising industrial demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending fueled by its highly engaged community, passionately advocating for the "OG meme" narrative of Rage Comics and actively building out an ecosystem with tools like RageMaker and RageGames. This dedicated base expresses strong conviction, viewing RAGE as significantly undervalued and poised for substantial long-term growth as they lead a "return to the memes" within the broader market upswing.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to significant community debate and anticipation surrounding potential positive announcements at the upcoming CES 2026. While many investors express frustration over recent price declines, a bullish contingent highlights analyst upgrades, institutional buying, and the company's strong fundamentals in agentic AI voice solutions for automotive and restaurant sectors, viewing current levels as a strategic buying opportunity for long-term growth.

BUUU Group Ltd. is a holding company, which operates through its subsidiaries, BU Creation and BU Workshop. Its subsidiaries engage in design, planning and production of face-to-face events, immersive environments and brand-based experiences for clients and venues, including event organizers, consumer brand marketers and retail shopping centers. The company was founded in 2017 and is headquartered in Hong Kong.

BUUU Group Ltd. - Ordinary Shares - Class A

BUUU Group Ltd

BUUU Group Ltd is experiencing extreme volatility and intense speculative trading, driven by comparisons to other high-flying, low-float Chinese stocks. While many traders are actively chasing rapid gains, a significant portion of the community warns of a potential pump and dump scenario, fueling a highly divided discussion.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending following positive Phase 3 trial data for its relacorilant candidate in platinum-resistant ovarian cancer, sparking community debate over market valuation and intense short-seller activity. Investors are also focused on an upcoming regulatory decision for relacorilant in Cushing's syndrome and promising survival data from its ALS program, fueling discussions about the company's long-term growth and potential for a significant short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending with high anticipation for multiple imminent FDA decisions, including a PDUFA date for its motion sickness drug, Tradipitant, and an expedited re-review for Hetlioz in jet lag. The community is actively discussing Tradipitant's significant potential in addressing GLP-1 induced nausea, viewing these regulatory catalysts as crucial for a re-rating given the company's improved relationship with the FDA. Investors are keenly watching for outcomes that could lead to considerable stock movement, drawing comparisons to other recent biotech approvals.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is trending on expectations of a significant refinancing wave and broader housing market recovery as monetary policy is anticipated to ease, positioning its integrated mortgage and fintech platform for growth. Community discussions highlight the company's strong technical setup, strategic advantages from its full ecosystem including Mr. Cooper and Redfin, and the potential for increased operating leverage through AI-driven efficiency. While many foresee substantial upside from cycle normalization, some caution against expecting a repeat of past rapid price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Protagenic Therapeutics, Inc. (PTIX) jumped 244% on Monday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pressviewer.com/profiles/investor/NewsPrint.asp?v=6&amp;b=2612&amp;ID=145678&amp;m=rl&amp;g=1834">announced</a> its merger with private pharmaceutical firm Phytanix Bio Inc.Protagenic said the two companies have entered into a definitive share exchange agreement, under which they will combine in an all-stock transaction.The combined entity will be called Phytanix, Inc., and will bring together the two companies’ pipelines focused on stress-related and central nervous system (CNS) disorders. While Protagenic makes peptides for stress-related disorders, Phytanix Bio specializes in developing medicines manufactured from cannabinoids and "cannabinoid-like" molecules.The combined entity will have five preclinical assets and one clinical-stage asset, Protagenic added.Protagenic executive chairman Garo H. Armen noted that the combination aligns two pipelines with complementary assets and expertise to develop drugs in neuropsychiatry, CNS, and other disorders.Protagenic said that post-combination, pre-financing ownership will be approximately 35% for the company's pre-combination stockholders and approximately 65% for Phytanix Bio stockholders on a fully diluted basis.Protagenic had announced a 1-for-14 reverse stock split of its issued and outstanding common stock earlier this month to bring the company into compliance with the minimum bid price requirement for continued listing on Nasdaq.On Stocktwits, retail sentiment around Protagenic jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_19_at_10_28_13_AM_png_a07fae3fc6.webp" alt="PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits" width="628" height="65"><figcaption>PTIX's Sentiment Meter and Message Volume as of 10:30 a.m. ET on May 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes the stock could rally further toward $15.<stembedurl>https://stocktwits.com/cjstocksup/message/615100995</stembedurl><a href="https://stocktwits.com/symbol/PTIX">PTIX stock</a> gained over 43% this year but is down by about 48% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/netflix-stock-edges-lower-after-jp-morgan-downgrade-despite-higher-price-target/ch0cubqRb82">Netflix Stock Edges Lower After JPMorgan Downgrade Despite Higher Price Target</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Protagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely Bullish

The new entity will be called Phytanix, Inc., and it will combine the two companies’ pipelines focused on stress-related and CNS disorders.

Equity

Protagenic Therapeutics, Inc. operates as a biotechnology company. It engages in the discovery and development of therapeutics to treat stress-related disorders including post-traumatic stress disorder, depression, anxiety, and drug & alcohol addiction. The firm offers PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

PTIX
Protagenic Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PTIX News

PTIXProtagenic Therapeutics Inc